Invention Grant
- Patent Title: Targeted antibodies directed to DLL4
- Patent Title (中): 针对DLL4的靶向抗体
-
Application No.: US12562268Application Date: 2009-09-18
-
Publication No.: US08192738B2Publication Date: 2012-06-05
- Inventor: Vahe Bedian , David Jenkins , Ian Foltz
- Applicant: Vahe Bedian , David Jenkins , Ian Foltz
- Applicant Address: US MD Gaithersburg
- Assignee: MedImmune, LLC
- Current Assignee: MedImmune, LLC
- Current Assignee Address: US MD Gaithersburg
- Agency: MedImmune, LLC
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/18 ; C07K14/435
Abstract:
The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
Public/Granted literature
- US20100196385A1 TARGETED BINDING AGENTS DIRECTED TO DLL4 AND USES THEREOF 524 Public/Granted day:2010-08-05
Information query
